The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM) (NLSDM)
|ClinicalTrials.gov Identifier: NCT01527318|
Recruitment Status : Completed
First Posted : February 7, 2012
Last Update Posted : May 14, 2013
Neutral Lipid Storage Disease With Myopath (NLSDM) is a disease caused by a defect in the PNPLA2 gene encoding ATGL. Patients with NLSDM accumulate triglycerides and exhibit muscle weakness, cardiac failure and hepatosteatosis. Most of these patients die at young age due to cardiac failure. Not much is known about the underlying mechanisms, though recently it was discovered that PPAR activation in ATGL-/- mice was impaired leading to decreased mitochondrial function, lipid accumulation and cardiac failure resulting in death at young age. Activation of PPARs, by treatment with fibrates rescued the phenotype and reduced mortality rates in these mice. These findings may have a major impact for patients with NLSDM if these results can be translated to humans. Therefore, the investigators would like to evaluate the beneficial effects of fibrate treatment on muscle mitochondrial and cardiac function in patients with NLSDM.
Patients will be treated with fibrates during a period of 28 weeks. Baseline measurements will be performed prior to the study and after treatment. Cardiac and muscular lipid accumulation, cardiac function, mitochondrial function and insulin sensitivity will be assessed during these baseline measurements.
|Condition or disease||Intervention/treatment||Phase|
|Neutral Lipid Storage Disease||Drug: Fibrate treatment||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||6 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM)|
|Study Start Date :||August 2011|
|Primary Completion Date :||December 2012|
|Study Completion Date :||December 2012|
Experimental: Fibrate Treatment
Patients will be treated during 28 weeks with a fibrate to assess the effects of PPAR activation on the NLSDM disease.
Drug: Fibrate treatment
Patients will receive a dosage of 400mg Bezafibrate every day during 28 weeks
- mitochondrial function [ Time Frame: 28 weeks ]mitochondrial function will be measured in vivo with 1H-MRS by pCr-recovery and ex vivo by high resolution respirometry.
- lipid accumulation [ Time Frame: 28 weeks ]Lipid accumulation will be measured both by 1H-MRS as CH/H2O ratio's in the Tibialis anterior muscle, as well as quantified from skeletal muscle biopsy with ORO from the vastus lateralis muscle.
- Cardiac function [ Time Frame: 28 weeks ]Cardiac function will be measured with ultrasound and be assessed by 2 blinded cardiologists.
- Insulin sensitivity [ Time Frame: 28 weeks ]This will be assessed by an euglycemic hyperinsulenemic clamp and whole body isulin sensitivity will be expressed with the M-value.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01527318
|Maastricht University Medical Center|
|Maastricht, Limburg, Netherlands, 6200MD|